DBVT

SEC source: 0001209191-23-045641 · doc4.xml · nonDerivative · entry 2

Mohideen Pharis · CIK 0001760395 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,700

F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

F3 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit RSU award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-045640 · doc4.xml · derivative · entry 2

Robitaille Sebastien · CIK 0001838818 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Ordinary Shares · 65,000 shares

Expires 2032-11-21

F3 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0242 to EURO 1.00 as of November 21, 2022.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-045640 · doc4.xml · nonDerivative · entry 1

Robitaille Sebastien · CIK 0001838818 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,500

F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

F2 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 21, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-045641 · doc4.xml · derivative · entry 5

Mohideen Pharis · CIK 0001760395 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Ordinary Shares · 100,000 shares

Expires 2032-07-29

F7 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.0226 to EURO 1.00 as of July 29, 2022.

F8 · derivative.exercise_date: 25% of the shares subject to the option vest on July 29, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-23-045641 · doc4.xml · nonDerivative · entry 1

Mohideen Pharis · CIK 0001760395 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,200

F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

F2 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on July 29, 2023, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-22-036411 · doc4.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 11,732,979

Underlying: Ordinary Shares · 11,732,979 shares

Expires 2032-06-13

F7 · derivative.exercise_price: Exercisable for 0.10 EUR per warrant on a 1-for-1 basis into Ordinary Shares.

F8 · price: Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants ("Pre-Funded Warrants"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate.

F8 · derivative.exercise_date: Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants ("Pre-Funded Warrants"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F8 · ownership.nature: Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants ("Pre-Funded Warrants"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate.

SEC source: 0001209191-22-036411 · doc4.xml · derivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,383,352

Underlying: Ordinary Shares · 1,383,352 shares

Expires 2032-06-13

F7 · derivative.exercise_price: Exercisable for 0.10 EUR per warrant on a 1-for-1 basis into Ordinary Shares.

F8 · price: Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants ("Pre-Funded Warrants"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate.

F8 · derivative.exercise_date: Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants ("Pre-Funded Warrants"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate.

F2 · ownership.nature: As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and the Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to the Offering, 667 and Life Sciences also purchased 1,383,352 and 11,732,979 warrants ("Pre-Funded Warrants"), respectively, with an exercise price of 0.10 EUR and an expiration date of June 13, 2032 exercisable immediately at the option of the holder on a 1-for-1 basis into Ordinary Shares to the extent that such holders, together with any other holders the holdings of which are assigned pursuant to the Pre-funded Warrant or pertinent law, would beneficially own, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, no more than 9.99% of the outstanding Ordinary Shares immediately prior to or following such exercise, at an offering price of 2.90 EUR per Pre-Funded Warrant, totaling 13,116,331 Pre-Funded Warrants in the aggregate.

SEC source: 0001209191-22-036411 · doc4.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 14,575,984

F6 · price: 667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the "Offering") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: As a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F6 · ownership.nature: 667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the "Offering") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate.

SEC source: 0001209191-22-036411 · doc4.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,585,054

F6 · price: 667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the "Offering") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate.

F2 · ownership.nature: As a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Ordinary Shares or ADS, as applicable, reported in column 5 of Table I and the Pre-Funded Warrants (as defined below) reported in column 9 of Table II directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: 667 and Life Sciences, pursuant to a Securities Purchase Agreement with the Issuer, purchased in a private investment in public equity financing that closed on June 13, 2022 (the "Offering") 1,252,432 and 10,622,568 Ordinary Shares, respectively, at the offering price of 3.00 EUR per share, totaling 11,875,000 Ordinary Shares in the aggregate.

SEC source: 0001209191-21-066789 · doc4.xml · derivative · entry 1

Tasse Daniel · CIK 0001502785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 274,000

Underlying: Ordinary Shares · 274,000 shares

Expires 2031-11-22

F1 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021.

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

F3 · derivative.underlying: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

SEC source: 0001209191-21-066788 · doc4.xml · derivative · entry 2

Mohideen Pharis · CIK 0001760395 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,400

Underlying: Ordinary Shares · 95,400 shares

Expires 2031-11-22

F3 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

F1 · derivative.underlying: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

SEC source: 0001209191-21-066788 · doc4.xml · nonDerivative · entry 1

Mohideen Pharis · CIK 0001760395 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,200

F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

F2 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-21-066786 · doc4.xml · derivative · entry 2

Robitaille Sebastien · CIK 0001838818 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Ordinary Shares · 51,000 shares

Expires 2031-11-22

F3 · derivative.exercise_price: This exercise price is in US Dollars and reflects the conversion of EURO to USD at an exchange rate of $1.1278 to EURO 1.00 as of November 22, 2021.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

F1 · derivative.underlying: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

SEC source: 0001209191-21-066786 · doc4.xml · nonDerivative · entry 1

Robitaille Sebastien · CIK 0001838818 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,500

F1 · security: The ordinary shares may be represented by American Depositary Shares, each of which currently represents one-half of one ordinary share.

F2 · shares: Represents the Issuer's ordinary shares underlying a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one ordinary share. 25% of the shares underlying the RSU vest on November 22, 2022, with the remaining shares vesting in six equal semi-annual installments thereafter, subject in each case to the Reporting Person continuing to provide service through each such date.

SEC source: 0001209191-21-039889 · doc4.xml · derivative · entry 1

Ndu Adora · CIK 0001865210 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,837

Underlying: Ordinary Shares · 6,837 shares

Expires 2025-06-10

F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

SEC source: 0001209191-21-039882 · doc4.xml · derivative · entry 1

DE ROSEN MICHEL · CIK 0001187148 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,837

Underlying: Ordinary Shares · 6,837 shares

Expires 2025-06-10

F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

SEC source: 0001209191-21-039886 · doc4.xml · derivative · entry 1

MORRIS TIMOTHY E · CIK 0001191286 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,837

Underlying: Ordinary Shares · 6,837 shares

Expires 2025-06-10

F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

SEC source: 0001209191-21-039890 · doc4.xml · derivative · entry 1

SOLAND DANIEL B · CIK 0001318485 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,837

Underlying: Ordinary Shares · 6,837 shares

Expires 2025-06-10

F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

SEC source: 0001209191-21-039884 · doc4.xml · derivative · entry 1

Monges Viviane · CIK 0001838204 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Ordinary Shares · 5,000 shares

Expires 2025-06-10

F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

SEC source: 0001209191-21-039881 · doc4.xml · derivative · entry 1

Rao Madduri Ravin · CIK 0001792006 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,837

Underlying: Ordinary Shares · 6,837 shares

Expires 2025-06-10

F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.

F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021.